Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
(NY:
MAIA
)
3.080
+0.190 (+6.57%)
Official Closing Price
Updated: 8:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MAIA
< Previous
1
2
3
Next >
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
April 30, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
April 29, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces $1.00 Million Private Placement
April 23, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer
October 31, 2023
Via
ACCESSWIRE
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
April 05, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
March 28, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
March 26, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces $1.33 Million Private Placement
March 26, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement
March 22, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board
March 21, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
March 07, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting
March 06, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
March 06, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
March 05, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
February 07, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds
January 24, 2024
From
MAIA Biotechnology
Via
Business Wire
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
January 17, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
January 05, 2024
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
December 19, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
November 17, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer
November 17, 2023
Via
ACCESSWIRE
MAIA Biotechnology Announces $4 Million Registered Direct Offering
November 15, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
November 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
November 07, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO
October 30, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
October 24, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023
October 19, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy
October 17, 2023
Via
ACCESSWIRE
MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023
October 17, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer
October 12, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.